Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?

The discovery of new drugs for treating the new coronavirus (SARS-CoV-2) or repurposing those already in use for other viral infections is possible through understanding of the viral replication cycle and pathogenicity. This article highlights the advantage of targeting one of the non-structural pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Habtemariam, Solomon, Nabavi, Seyed Fazel, Banach, Maciej, Berindan-Neagoe, Ioana, Sarkar, Kasturi, Sil, Parames C., Nabavi, Seyed Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IMSS. Published by Elsevier Inc. 2020
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261434/
https://www.ncbi.nlm.nih.gov/pubmed/32536457
http://dx.doi.org/10.1016/j.arcmed.2020.05.024
_version_ 1783540501581922304
author Habtemariam, Solomon
Nabavi, Seyed Fazel
Banach, Maciej
Berindan-Neagoe, Ioana
Sarkar, Kasturi
Sil, Parames C.
Nabavi, Seyed Mohammad
author_facet Habtemariam, Solomon
Nabavi, Seyed Fazel
Banach, Maciej
Berindan-Neagoe, Ioana
Sarkar, Kasturi
Sil, Parames C.
Nabavi, Seyed Mohammad
author_sort Habtemariam, Solomon
collection PubMed
description The discovery of new drugs for treating the new coronavirus (SARS-CoV-2) or repurposing those already in use for other viral infections is possible through understanding of the viral replication cycle and pathogenicity. This article highlights the advantage of targeting one of the non-structural proteins, helicase (nsp13), over other SARS-CoV-2 proteins. Highlighting the experience gained from targeting Nsp13 in similar coronaviruses (SARS-CoV and MERS) and known inhibitors, the article calls for research on helicase inhibitors as potential COVID-19 therapy.
format Online
Article
Text
id pubmed-7261434
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher IMSS. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-72614342020-06-01 Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy? Habtemariam, Solomon Nabavi, Seyed Fazel Banach, Maciej Berindan-Neagoe, Ioana Sarkar, Kasturi Sil, Parames C. Nabavi, Seyed Mohammad Arch Med Res Opinion The discovery of new drugs for treating the new coronavirus (SARS-CoV-2) or repurposing those already in use for other viral infections is possible through understanding of the viral replication cycle and pathogenicity. This article highlights the advantage of targeting one of the non-structural proteins, helicase (nsp13), over other SARS-CoV-2 proteins. Highlighting the experience gained from targeting Nsp13 in similar coronaviruses (SARS-CoV and MERS) and known inhibitors, the article calls for research on helicase inhibitors as potential COVID-19 therapy. IMSS. Published by Elsevier Inc. 2020-10 2020-05-31 /pmc/articles/PMC7261434/ /pubmed/32536457 http://dx.doi.org/10.1016/j.arcmed.2020.05.024 Text en © 2020 IMSS. Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Opinion
Habtemariam, Solomon
Nabavi, Seyed Fazel
Banach, Maciej
Berindan-Neagoe, Ioana
Sarkar, Kasturi
Sil, Parames C.
Nabavi, Seyed Mohammad
Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?
title Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?
title_full Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?
title_fullStr Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?
title_full_unstemmed Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?
title_short Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?
title_sort should we try sars-cov-2 helicase inhibitors for covid-19 therapy?
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261434/
https://www.ncbi.nlm.nih.gov/pubmed/32536457
http://dx.doi.org/10.1016/j.arcmed.2020.05.024
work_keys_str_mv AT habtemariamsolomon shouldwetrysarscov2helicaseinhibitorsforcovid19therapy
AT nabaviseyedfazel shouldwetrysarscov2helicaseinhibitorsforcovid19therapy
AT banachmaciej shouldwetrysarscov2helicaseinhibitorsforcovid19therapy
AT berindanneagoeioana shouldwetrysarscov2helicaseinhibitorsforcovid19therapy
AT sarkarkasturi shouldwetrysarscov2helicaseinhibitorsforcovid19therapy
AT silparamesc shouldwetrysarscov2helicaseinhibitorsforcovid19therapy
AT nabaviseyedmohammad shouldwetrysarscov2helicaseinhibitorsforcovid19therapy

Ejemplares similares